Filgotinib: Clinical Trials

17 trials of Filgotinib, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

7 completed, 4 terminated, 3 recruiting, 2 withdrawn. 17 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	17	Completed 7, Terminated 4, Recruiting 3, Withdrawn 2, Active not recruiting 1

Follow Filgotinib: new trials by email Literature Review of Filgotinib trials Research Report on Filgotinib

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents Filgotinib - Polyarticular Course Juvenile Idiopathic Arthritis	Phase 3	Recruiting	Alfasigma S.p.A.	65	2026-05-21	2026-06-12
OLE Study With Filgotinib in JIA Filgotinib - Juvenile Idiopathic Arthritis (JIA)	Phase 3	Recruiting	Alfasigma S.p.A.	80	2026-04-20	2026-08-10
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Filgotinib - Ulcerative Colitis	Phase 3	Recruiting	Alfasigma S.p.A.	80	2025-09-29	2026-10-20
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis Filgotinib, Placebo - Axial Spondyloarthritis	Phase 3	Active not recruiting	Alfasigma S.p.A.	495	2023-04-05	2025-12-04
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission Filgotinib, Placebo - Ulcerative Colitis	Phase 3	Terminated	Lakefront Biotherapeutics NV	22	2022-07-26	2024-10-04
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy Filgotinib, Placebo to Match Filgotinib - Ankylosing Spondylitis	Phase 3	Withdrawn	Gilead Sciences		2020-12-01	2021-01-11
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy Filgotinib, Placebo to Match Filgotinib - Ankylosing Spondylitis	Phase 3	Withdrawn	Gilead Sciences		2020-12-01	2021-01-11
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy Filgotinib, Adalimumab, Placebo to match filgotinib - Psoriatic Arthritis	Phase 3	Terminated	Gilead Sciences	67	2019-12-03	2022-05-16
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy Filgotinib, Placebo to match filgotinib - Psoriatic Arthritis	Phase 3	Terminated	Gilead Sciences	106	2019-11-13	2022-03-18
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease Filgotinib, Placebo - Crohn's Disease	Phase 3	Terminated	Lakefront Biotherapeutics NV	1188	2017-03-17	2024-07-10
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis Filgotinib, Placebo to match filgotinib - Rheumatoid Arthritis	Phase 3	Completed	Alfasigma S.p.A.	2731	2017-02-28	2026-07-27
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Filgotinib, Placebo - Ulcerative Colitis	Phase 3	Completed	Alfasigma S.p.A.	1173	2017-02-23	2026-09-17
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Filgotinib, PTM filgotinib - Ulcerative Colitis	Phase 3	Completed	Gilead Sciences	1351	2016-11-14	2021-04-21
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Filgotinib, Placebo - Crohn's Disease	Phase 3	Completed	Lakefront Biotherapeutics NV	1372	2016-10-31	2023-12-18
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Filgotinib, Placebo to match filgotinib, Adalimumab - Rheumatoid Arthritis	Phase 3	Completed	Gilead Sciences	1759	2016-08-30	2021-06-09
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy Filgotinib, Placebo to match filgotinib, MTX - Rheumatoid Arthritis	Phase 3	Completed	Gilead Sciences	1252	2016-08-08	2021-06-01
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment Filgotinib, Placebo to match filgotinib, csDMARDs - Rheumatoid Arthritis	Phase 3	Completed	Gilead Sciences	449	2016-07-27	2021-05-13

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding